China channel feed

John Oyler, BeiGene CEO (Paul Yeung/Bloomberg via Getty Images)

Bris­tol My­ers wants to pull out of its Abrax­ane deal in Chi­na. BeiGene says no way

A year and a half after Chinese officials ordered BeiGene to stop selling Bristol Myers Squibb’s Abraxane in the wake of an alarming inspection of a US facility, the manufacturing issues at the root of the import suspension still appear unresolved.

And Bristol Myers wants to axe the Abraxane supply deal altogether.

But BeiGene, which is currently in arbitration proceedings against its Big Pharma partner, won’t let it off the hook so easily.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,100+ biopharma pros reading Endpoints daily — and it's free.

Alan Sandler, Zai Lab president and head of global development, oncology (Roche via YouTube)

Un­fazed by OS flop, Zai Lab eyes im­mi­nent Chi­na fil­ing for Macro­Gen­ic­s' HER2 drug

MacroGenics’ anti-HER2 drug may have run into some trouble with its US data, but in China, partners at Zai Lab are getting a clear go-ahead signal.

The antibody, margetuximab, aced a bridging study among Chinese patients with advanced HER2 breast cancer, with a hazard ratio for progression-free survival of 0.69 favoring the combination of margetuximab plus chemotherapy, suggesting consistent safety and efficacy as seen in the global population. Zai Lab is now plotting a BLA submission by the end of the year — one year after MacroGenics scored its first FDA approval.

Sen. Tom Cotton (R-AR) (Michael Brochstein/Sipa USA/Sipa via AP Images)

Black­list Chi­nese ge­net­ic se­quenc­ing com­pa­nies, law­mak­ers ar­gue — cit­ing po­ten­tial for 'bioweapons,' na­tion­al se­cu­ri­ty risk

As Chinese biotech companies spread their wings globally, a pair of lawmakers — and known China hawks on the Hill — are calling for a prominent genetic sequencing player to be blacklisted.

Sen. Tom Cotton (R-AR) and Rep. Mike Gallagher (R-WI) singled out Beijing Genomics Institute, which has rebranded itself as BGI Genomics, as a company that should be added to multiple sanction lists along with other, unnamed Chinese biotech companies.

The I-Mab team from L-R: CFO Jielun Zhu; President Zheru Zhang; Founder and chairman Jingwu Zang; CEO Joan Shen; and chief commercial officer Ivan Yifei Zhu

I-Mab in talks about deals, stake sale to build on $3B Ab­b­Vie al­liance — Bloomberg

A year after I-Mab made headlines with its $2.9 billion deal licensing a CD47 drug to AbbVie, the Chinese biotech is reportedly holding early talks with global pharma players about partnerships and potential investment.

The Shanghai-based, Nasdaq-listed company is mulling “clinical and commercial cooperation in China and a potential equity stake sale,” Bloomberg reported, quoting people familiar with the matter. Both US and European drugmakers are among the suitors involved in preliminary discussions.

Kim Kjøller, Union Therapeutics CEO

In­novent bets $250M+ on Union's PDE4 in­hibitor ahead of a PhII read­out

A year after plucking orismilast from Leo Pharmaceuticals’ pipeline — and without publishing any mid-stage data — Union Therapeutics is already making a pretty penny on the oral PDE4 inhibitor.

Innovent Biologics is shelling out $20 million upfront for development and commercialization rights to Union’s “Phase III-ready” oral formulation of orismilast in China, the companies said early Tuesday morning. Hoping to one-up Amgen’s blockbuster PDE4 inhibitor Otezla in terms of potency, Union’s been pushing the candidate through Phase II trials in skin conditions like psoriasis, atopic dermatitis and hidradenitis suppurativa.

Chi­nese biotech Ever­est signs $550M+ li­cens­ing deal for BTK in­hibitors on heels of Covid-19 pact

Everest Medicines is on a roll with two licensing deals in one week.

The Shanghai-based biotech has paid Sinovent and SinoMab $12 million upfront for the rights to a BTK inhibitor for renal diseases, the company announced Thursday. The deal comes just days after Everest came away with rights to a Covid-19 vaccine in China, Taiwan, Singapore, Thailand and Indonesia.

Everest will pay Sinovent and SinoMab up to $549 million in milestone payments and royalties. The agreement includes tech transfer of Sinovent and SinoMab’s manufacturing process for the candidate, named XNW1011.

Kerry Blanchard, Everest CEO

Trans-Pa­cif­ic pow­er play­er Ever­est jumps on mR­NA vac­cine deal with Prov­i­dence, pay­ing $100M up­front to tap plat­form play

Everest is jumping aboard the Covid-19 mRNA vaccine train.

While China has used other vaccine technologies to vaccinate its population, companies are starting to explore the use of mRNA vaccines in Asian markets. Everest is now the latest company to focus on the Chinese market in a deal with Canadian biotech Providence Therapeutics.

As part of the deal, Providence will get $100 million upfront in cash, combined with an additional up to $400 million in profit-sharing on the Covid-19 vaccines and milestone payments on collaborative and additional products.

James Li, JW Therapeutics CEO

Sis­ter to Juno's liso-cel, JW's rel­ma-cel lands sec­ond-ever CAR-T ap­proval in Chi­na

Juno may have stumbled its way to a distant third finish in the CD19 CAR-T race, but its joint venture in China is heading off to a thriving start.

JW Therapeutics, which took its name from co-founders Juno and WuXi AppTec, has scored the second-ever CAR-T approval by China’s National Medical Product Administration just weeks after Fosun Kite, another joint venture, claimed first.

Now sanctioned to treat relapsed or refractory large B-cell lymphoma patients who’ve had two or more lines of systemic therapy, relma-cel was developed on the same cell process platform that spawned Juno’s liso-cel — now Bristol Myers Squibb’s Breyanzi — but a different drug in that it’s tailored for Chinese needs.

Lan Huang, BeyondSpring CEO

Play­ing a sur­pris­ing­ly hot hand, Be­yond­Spring nails a $200M Chi­na deal in wake of a piv­otal suc­cess

BeyondSpring has been on a roll lately.

Just a few weeks ago, the New York-based biotech shocked investors and analysts with how effective the company’s molecule, plinabulin, was on cancer patients’ longevity. Now, the biotech has forged a deal with a major player in the Asian market for the drug.

BeyondSpring announced this morning a commercialization and co-development agreement between its Chinese subsidiary Wanchunbulin and China’s Jiangsu Hengrui Pharmaceuticals.

Bo Ying, Abogen CEO (Xi'an Jiaotong-Liverpool University)

Chi­na's Abo­gen, a small mR­NA up­start, sets a biotech record with mam­moth $700M Se­ries C

A little-known startup from China shocked the biotech world Thursday with a record-breaking Series C, showing how deep-pocketed investors are angling to get a piece of the mRNA vaccine pie.

Abogen Biosciences closed a staggering $700 million round Thursday, the company announced, largely to push forward its mRNA-based Covid-19 vaccine candidate. But the funds will also help the Suzhou, China-based biotech vastly expand its other vaccine and oncology programs, while building out its manufacturing capabilities to support those efforts.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,100+ biopharma pros reading Endpoints daily — and it's free.